Skip to content

PTC Therapeutics

US · PTCT #2071 by market cap Listed 1970
56.42 -1.91 -3.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.6 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
124.86% +1.65pp
Institutions
473 +1
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund94.78%
Hedge Fund19.50%
Public Company5.78%
Individual/Insider2.38%
Private Company2.29%
Government Pension Fund1.14%
Insurance Company0.63%
Endowment Fund0.49%
Family Office/Trust0.13%

Top holders as of 2026-09-30

BlackRock 17.23% · 14.40M sh
RTW Investments, LP 9.27% · 7.75M sh
Janus Henderson Group plc 8.66% · 7.24M sh
State Street Global Advisors 6.60% · 5.51M sh
Vanguard Portfolio Management, LLC 5.96% · 4.98M sh
Wellington Management Group 4.94% · 4.13M sh
Vanguard Capital Management, LLC 4.33% · 3.62M sh
The Toronto-Dominion Bank 2.59% · 2.17M sh
Geode Capital Management, LLC 2.57% · 2.15M sh
UBS Asset Management 2.40% · 2.01M sh
Westfield Capital Management Company, L.P. 2.34% · 1.96M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 7 buys · 40 sells

NameRoleStake
Michael Schmertzler Independent Chairperson 1.74%
Matthew Klein Chief Executive Officer 0.19%
Mark Boulding Chief Legal Officer 0.13%
Christine Utter Senior VP, Chief Accounting Officer & Head of People Services 0.05%
Pierre Gravier Chief Financial Officer 0.04%
Lee Golden Chief Medical Officer 0.04%
Eric Pauwels Chief Business Officer 0.03%
Hege Sollie-Zetlmayer Director 0.02%
Glenn Steele Independent Director 0.02%
Mary Smith Independent Director 0.02%

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-13 Michael Schmertzler Independent Chairperson Automatic Disposition -2,500 $59.52–60.14
2026-10-08 Mark Boulding Chief Legal Officer Derivative Exercise and Sale -192 $39.42–64.26
2026-10-06 Michael Schmertzler Independent Chairperson Automatic Disposition -2,500 $63.38–63.95
2026-10-05 Mark Boulding Chief Legal Officer Derivative Exercise and Sale -2,073 $39.42–64.16
2026-10-05 Mark Boulding Chief Legal Officer Intent to Sell (Form 144) -435 $64.16
2026-10-04 Mark Boulding Chief Legal Officer Intent to Sell (Form 144) -1,638 $64.03
2026-09-29 Glenn Steele Independent Director Derivative Exercise and Sale -12,000 $11.23–65.16
2026-09-16 Michael Schmertzler Independent Chairperson Automatic Disposition -20,000 $66.58–68.45
2026-09-09 Michael Schmertzler Independent Chairperson Automatic Disposition -20,000 $67.34–68.67
2026-08-26 Michael Schmertzler Independent Chairperson Automatic Disposition -25,000 $71.55–73.18
2026-08-19 Michael Schmertzler Independent Chairperson Automatic Disposition -25,000 $70.78–73.67
2026-08-18 Michael Schmertzler Independent Chairperson Intent to Sell (Form 144) -50,000 --
2026-08-16 Mark Boulding Chief Legal Officer Derivative Exercise and Sale -2,813 $25.69–72.90
2026-08-03 Matthew Klein Chief Executive Officer Open Market Disposition -10,292 $68.57
2026-07-27 Hege Sollie-Zetlmayer Director Other Acquisition +6,000 --
2026-07-27 Hege Sollie-Zetlmayer Director Other Derivative Acquisition +5,213 $75.39
2026-07-27 Hege Sollie-Zetlmayer Director Initial Statement of Beneficial 0 --
2026-07-13 Pierre Gravier Chief Financial Officer Open Market Disposition -3,494 $80.35
2026-07-08 Neil Almstead Chief Technical Operations Officer Derivative Exercise and Sale -2,464 $46.54–90.25
2026-07-08 Mary Smith Independent Director Derivative Exercise and Sale -15,834 $42.95–90.00

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

PTC Therapeutics discussion 0 comments

Add a comment